Hsbc Global Res Comments on Biogen Inc.’s FY2027 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Hsbc Global Res upped their FY2027 earnings estimates for shares of Biogen in a research report issued to clients and investors on Monday, July 8th. Hsbc Global Res analyst M. Herholdt now forecasts that the biotechnology company will earn $22.39 per share for the year, up from their previous estimate of $22.33. The consensus estimate for Biogen’s current full-year earnings is $15.63 per share. Hsbc Global Res also issued estimates for Biogen’s FY2028 earnings at $24.30 EPS.

A number of other research firms have also weighed in on BIIB. Wedbush raised their target price on shares of Biogen from $213.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, April 25th. Royal Bank of Canada restated an “outperform” rating and set a $317.00 price target on shares of Biogen in a report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of Biogen in a report on Thursday, May 23rd. Barclays cut their price target on shares of Biogen from $215.00 to $200.00 and set an “equal weight” rating for the company in a report on Thursday, April 25th. Finally, UBS Group cut their price target on shares of Biogen from $250.00 to $214.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Ten analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $286.50.

Biogen Trading Up 1.7 %

BIIB opened at $236.80 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.10 and a quick ratio of 1.32. The company’s 50 day simple moving average is $226.25 and its two-hundred day simple moving average is $227.24. Biogen has a 1-year low of $189.44 and a 1-year high of $281.68. The firm has a market capitalization of $34.48 billion, a price-to-earnings ratio of 29.56, a price-to-earnings-growth ratio of 2.30 and a beta of -0.04.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.45 by $0.22. Biogen had a net margin of 12.07% and a return on equity of 14.83%. The business had revenue of $2.29 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period last year, the company posted $3.40 EPS. The business’s revenue was down 7.0% on a year-over-year basis.

Hedge Funds Weigh In On Biogen

Several institutional investors have recently modified their holdings of BIIB. CX Institutional purchased a new stake in shares of Biogen during the 2nd quarter worth $233,000. Valeo Financial Advisors LLC lifted its position in shares of Biogen by 40.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,986 shares of the biotechnology company’s stock worth $460,000 after purchasing an additional 574 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its position in shares of Biogen by 39.4% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 7,486 shares of the biotechnology company’s stock worth $1,735,000 after purchasing an additional 2,115 shares during the last quarter. CWM LLC lifted its position in shares of Biogen by 1.7% during the 2nd quarter. CWM LLC now owns 3,765 shares of the biotechnology company’s stock worth $873,000 after purchasing an additional 62 shares during the last quarter. Finally, CVA Family Office LLC lifted its position in shares of Biogen by 120.4% during the 2nd quarter. CVA Family Office LLC now owns 313 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 171 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.